Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | SVP Chief Financial Officer | May 11, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,978 |
Reported balance
After 2026-05-11 transaction · row 1
1 source rowRow 1 · 2026-05-11 · Sale · Disposed 435 · Balance 85,978 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2026 Filed May 13, 2026 23:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 435 | $21.05 | $9,156.75 |
DisclosureSEC source: 0002065881-26-000004 · wk-form4_1778715805.xml · nonDerivative · entry 1 Vairavan Latha · CIK 0002065881 · SVP Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,978 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. Read SEC document |
| May 04, 2026 Filed May 6, 2026 22:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,341 | $23.61 | $31,661.81 |
DisclosureSEC source: 0002065881-26-000002 · wk-form4_1778105592.xml · nonDerivative · entry 1 Vairavan Latha · CIK 0002065881 · SVP Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,413 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 81 | $25.91 | $2,099.03 |
DisclosureSEC source: 0001628280-26-014325 · wk-form4_1772588527.xml · nonDerivative · entry 3 Vairavan Latha · CIK 0002065881 · SVP Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,754 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,772 | $25.16 | $69,744.91 |
DisclosureSEC source: 0001628280-26-014325 · wk-form4_1772588527.xml · nonDerivative · entry 2 Vairavan Latha · CIK 0002065881 · SVP Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,835 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $26.97 | $0.00 |
DisclosureSEC source: 0001628280-26-014325 · wk-form4_1772588527.xml · derivative · entry 4 Vairavan Latha · CIK 0002065881 · SVP Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-02-27 F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014325 · wk-form4_1772588527.xml · nonDerivative · entry 1 Vairavan Latha · CIK 0002065881 · SVP Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,607 F1 · kind: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 00:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,320 | $25.50 | $33,657.89 |
DisclosureSEC source: 0001628280-26-005568 · wk-form4_1770251062.xml · nonDerivative · entry 1 Vairavan Latha · CIK 0002065881 · SVP Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,607 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 23:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 88 | $24.72 | $2,175.23 |
DisclosureSEC source: 0002065881-25-000035 · wk-form4_1762385042.xml · nonDerivative · entry 1 Vairavan Latha · CIK 0002065881 · SVP Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,927 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.435 to $25.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 22:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 89 | $14.33 | $1,275.07 |
DisclosureSEC source: 0001787306-25-000117 · wk-form4_1754432928.xml · nonDerivative · entry 1 Vairavan Latha · CIK 0002065881 · SVP Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,015 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.98 to $14.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 06, 2025 Filed May 7, 2025 23:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $14.32 | $0.00 |
DisclosureSEC source: 0002065881-25-000005 · wk-form4_1746660587.xml · derivative · entry 2 Vairavan Latha · CIK 0002065881 · SVP Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-05-06 F2 · derivative.exercise_date: The options will vest and become exercisable as to 1/48th of the shares on each monthly anniversary of May 6, 2025 (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 06, 2025 Filed May 7, 2025 23:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002065881-25-000005 · wk-form4_1746660587.xml · nonDerivative · entry 1 Vairavan Latha · CIK 0002065881 · SVP Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,104 F1 · shares: Represents Restricted Stock Units ("RSUs") that will vest as to 25% of the RSUs on each annual anniversary of May 1, 2025 (the "Vesting Commencement Date"), beginning on May 1, 2026, subject to the Reporting Person's continued service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.